Skip to content
Alert Sign COVID-19 Updates: New Visitor Guidelines & Vaccine Update Close Alert Box
Hackensack UMC logo
  • GIVE NOW
  • 1-844-HMH-WELL
  • Find a Doctor
  • About
  • Location
  • Team
  • Services
  • Research
  • Donate

Clinical Trials

Find a DoctorOur LocationsAwards and Accreditation

Home  › Research  ›  Trials

Search for:

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy


Celgene, CC-90009-AML-002, PI Dr. Koprivnikar Title: An Exploratory Phase 1b Open-label Multi-arm Trial to Evaluate the Safety and Efficacy of CC-90009 in Combination with Anti-Leukemia Agents in Subjects with Acute Myeloid Leukemia


A Phase 2b, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly-Diagnosed Acute Myeloid Leukemia, Not Eligible for Standard Induction Therapy


A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy


A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)


A phase I multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in adults with newly diagnosed primary or secondary acute myeloid leukemia (AML) in morphologic complete remission with minimal residual disease (MRD)


An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)


An Exploratory Phase 1b Open-label Multi-arm Trial to Evaluate the Safety and Efficacy of CC-90009 in Combination with Anti-Leukemia Agents in Subjects with Acute Myeloid Leukemia


Randomized, open-label study of oral ABL001 versus bosutinib in patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors


A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia


Posts navigation

Next
View all types of trials

Types of Cancer / Trials

  • All
  • Breast
  • Breast-Surgical Oncology
  • Gastrointestinal
  • Genito-Urinary
  • Gynecologic
  • Head and Neck
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Neuro-oncology
  • Phase 1
  • Phase 1 (GI)
  • Phase 1 (L)
  • Phase 1 (Thoracic)
  • Skin and Soft Tissue
  • Thoracic (Lung)
  • Transplant

Recently Added Trials

  • A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
  • A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma.
  • A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma
  • A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
  • A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of NivolumabVersus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human EpidermalGrowth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

© 2021 Hackensack Meridian Health

  • About Us
  • Careers
  • Classes & Events
  • Contact Us
  • Donate
  • Financial Practices
  • Patients & Visitors
  • Privacy
  • Terms & Conditions